Bluelight (web forum)

Last updated
Bluelight
NicknameBluelight
PredecessorMDMA Clearinghouse
Formation1997;27 years ago (1997)
Legal statusNon-profit organization
Purpose Harm reduction, peer support, academic research, mental health, drug education, substance dependence recovery
HeadquartersMelbourne, Australia
Region served
International
Membership
465,000
Official language
English
Executive Director
Monica J. Barratt
Parent organization
Bluelight Communities Ltd.
Affiliations Multidisciplinary Association for Psychedelic Studies
Erowid
Tripsit
PillReports.net
Volunteers
50+
Website www.bluelight.org
Formerly called
Bluelight.ru, Bluelight.nu

Bluelight is a web-forum, research portal, online community, and non-profit organization dedicated to harm reduction in drug use. [1] [2] Its userbase includes current and former substance users, academic researchers, drug policy activists, and mental health advocates. [2] [3] [4] It is believed to be the largest online international drug discussion website in the world. [1] [5] As of February 2024, the website claims over 465,000 registered members. [6]

Contents

Bluelight has been utilized by academic researchers as a primary source of data in numerous publications. [1] [2] [7] [8] [9] Researchers also utilize the site to advertise research studies, recruit study participants, and better understand the world of substance use. [1] [2] Research groups and organizations that have partnered with Bluelight to recruit study participants include Imperial College London, [10] [11] Johns Hopkins University, [12] [13] [14] Health Canada, [15] Karlstad University, [16] Curtin University, [17] Macquarie University, [18] Columbia University, [19] [20] University of Pennsylvania, [21] University of Michigan, [22] [23] [24] [25] [26] [27] Toronto Metropolitan University (then known as Ryerson University), [28] and MAPS. [29]

Researchers have found that the most common reasons for substance users to visit Bluelight.org and similar online communities are to learn "how to use drugs safely" and "how to help others use drugs safely." [2] [22] [30]

Bluelight does not condemn or condone drug use, but instead advocates educating individuals to make informed decisions, connecting them with local harm reduction services, and providing them with evidence-based harm reduction resources and public safety notices. Bluelight emphasizes "meeting users where they are", and supporting them whether they wish to continue, moderate, or cease their substance use. [8] [30] [31]

In 2022, Bluelight launched an expansion to various social media platforms, most notably establishing a community on the instant messaging platform Discord dedicated to harm reduction, mental health, & peer support. [32] [33] As of February 2024, its Discord community is home to over 7,500 members. [33]

History

Bluelight.org was originally formed in 1997 as a message board on bluelight.net called the MDMA Clearinghouse. [34] The board was created as a side project by the owner of West Palm Beach design company Bluelight Designs. [35] 200-300 users joined the site between 1998-1999, but the site's servers were heavily limited and could only store a few threads at a time; this led to the creation of 'The New Bluelight' forum in May 1999 and the registration of the bluelight.nu domain in June 1999. [34]

The site began to explode in popularity in the early 2000s with the rise of MDMA in the club scene, amassing nearly 7,000 members by the year 2000 and 59,000 by the start of 2006. [34] [36]

The site switched to the bluelight.ru domain in October 2005, and switched again to bluelight.org in January 2014. [35]

In February 2022, Bluelight launched a social media initiative and spearheaded an expansion to other platforms. [32] The centerpiece of this expansion is a Discord community dedicated to harm reduction, mental health, & peer support. [33] The community brands itself as "a safe haven for people who are LGBTQIA+, neurodivergent, substance users, struggling with mental health, or just don't feel like they fit in anywhere else." [31]

As of February 2024, Bluelight's Discord community is home to over 7,500 members. [33]

In early 2024, Bluelight became a subsidiary of the Australian non-profit organization Bluelight Communities Ltd. [37]

Partnerships

In the early 2000s, Bluelight worked with reagent test supplier EZ-Test to promote the sale of drug checking kits.

In 2007, Bluelight partnered with the Multidisciplinary Association for Psychedelic Studies (MAPS), a non-profit organization working to raise awareness and understanding of psychedelic drugs through education, clinical research, and advocacy. [29] [34] MAPS utilized Bluelight to recruit participants for its first MDMA-assisted psychotherapy trial for PTSD. In 2013, the official MAPS forums were migrated to Bluelight. [38]

Bluelight's other partners include Erowid, a non-profit organization dedicated to education surrounding psychoactive drugs; Tripsit, a harm reduction education website; Pill Reports, a web-based database for drug checking results that was initially formed as an offshoot of the site; and the Global Drug Survey, an independent research organization focused on collecting data about substance use.

Notable users

See also

Related Research Articles

<span class="mw-page-title-main">Ayahuasca</span> South American psychoactive brew

Ayahuasca is a South American psychoactive brew, traditionally used by Indigenous cultures and folk healers in the Amazon and Orinoco basins for spiritual ceremonies, divination, and healing a variety of psychosomatic complaints. Originally restricted to areas of Peru, Brazil, Colombia and Ecuador, in the middle of 20th century it became widespread in Brazil in context of appearance of syncretic religions that use ayahuasca as a sacrament, like Santo Daime, União do Vegetal and Barquinha, which blend elements of Amazonian Shamanism, Christianity, Kardecist Spiritism, and African-Brazilian religions such as Umbanda, Candomblé and Tambor de Mina, later expanding to several countries across all continents, notably the United States and Western Europe, and, more incipiently, in Eastern Europe, South Africa, Australia, and Japan.

<span class="mw-page-title-main">Recreational drug use</span> Use of drugs with the primary intention to alter the state of consciousness

Recreational drug use is the use of one or more psychoactive drugs to induce an altered state of consciousness, either for pleasure or for some other casual purpose or pastime. When a psychoactive drug enters the user's body, it induces an intoxicating effect. Recreational drugs are commonly divided into three categories: depressants, stimulants, and hallucinogens.

<span class="mw-page-title-main">Psychedelic drug</span> Hallucinogenic class of psychoactive drug

Psychedelics are a subclass of hallucinogenic drugs whose primary effect is to trigger non-ordinary mental states and an apparent expansion of consciousness. Also referred to as classic hallucinogens or serotonergic hallucinogens, the term psychedelic is sometimes used more broadly to include various types of hallucinogens, such as those which are atypical or adjacent to psychedelia like salvia and MDMA, respectively. This article makes use of the narrower classical definition of psychedelics. Classic psychedelics generally cause specific psychological, visual, and auditory changes, and oftentimes a substantially altered state of consciousness. They have had the largest influence on science and culture, and include mescaline, LSD, psilocybin, and DMT.

A bad trip is a term describing an acute adverse psychological reaction to effects produced under the influence of psychoactive substances, namely psychedelics. To date, there is no clear definition of what constitutes a bad trip. Additionally, knowledge on the cause of bad trips and who may be vulnerable to such experiences are limited. Existing studies report that possible adverse reactions include, anxiety, panic, depersonalization, ego dissolution, paranoia, as well as physiological symptoms such as dizziness and heart palpitations. However, most studies indicate that the set and setting of substance use influence how people respond.

<span class="mw-page-title-main">Harm reduction</span> Public health policies which lessen negative aspects of problematic activities

Harm reduction, or harm minimization, refers to a range of intentional practices and public health policies designed to lessen the negative social and/or physical consequences associated with various human behaviors, both legal and illegal. Harm reduction is used to decrease negative consequences of recreational drug use and sexual activity without requiring abstinence, recognizing that those unable or unwilling to stop can still make positive change to protect themselves and others.

<span class="mw-page-title-main">Erowid</span> Non-profit educational organization

Erowid, also called Erowid Center, is a non-profit educational organization that provides information about psychoactive plants and chemicals.

Psychedelic therapy refers to the proposed use of psychedelic drugs, such as psilocybin, MDMA, LSD, and ayahuasca, to treat mental disorders. As of 2021, psychedelic drugs are controlled substances in most countries and psychedelic therapy is not legally available outside clinical trials, with some exceptions.

<span class="mw-page-title-main">Cohoba</span> Taíno term for a ceremony in which the ground seeds of the cojóbana tree were inhaled

Cohoba is a Taíno transliteration for a ceremony in which the ground seeds of the cojóbana tree were inhaled, the Y-shaped nasal snuff tube used to inhale the substance, and the psychoactive drug that was inhaled. Use of this substance produced a hallucinogenic, entheogenic, or psychedelic effect. The cojóbana tree is believed by some to be Anadenanthera peregrina although it may have been a generalized term for psychotropics, including the quite toxic Datura and related genera (Solanaceae). The corresponding ceremony using cohoba-laced tobacco is transliterated as cojibá. This was said to have produced the sense of a visionary journey of the kind associated with the practice of shamanism.

<span class="mw-page-title-main">Set and setting</span> Mindset and location of a drug experience

Set and setting, when referring to a psychedelic drug experience or the use of other psychoactive substances, means one's mindset and the physical and social environment in which the user has the experience. Set and setting are factors that can condition the effects of psychoactive substances: "Set" refers to the mental state a person brings to the experience, like thoughts, mood and expectations; "setting" to the physical and social environment. This is especially relevant for psychedelic experiences in either a therapeutic or recreational context.

Drug education is the planned provision of information, guidelines, resources, and skills relevant to living in a world where psychoactive substances are widely available and commonly used for a variety of both medical and non-medical purposes, some of which may lead to harms such as overdose, injury, infectious disease, or addiction. The two primary approaches to drug education are harm-reduction education and abstinence-based education.

<span class="mw-page-title-main">Polysubstance use</span> Use of multiple psychoactive substances

Polysubstance use or poly drug use refers to the use of combined psychoactive substances. Polysubstance use may be used for entheogenic, recreational, or off-label indications, with both legal and illegal substances. In many cases one drug is used as a base or primary drug, with additional drugs to leaven or compensate for the side effects, or tolerance, of the primary drug and make the experience more enjoyable with drug synergy effects, or to supplement for primary drug when supply is low.

Sex and drugs date back to ancient humans and have been interlocked throughout human history. Both legal and illegal, the consumption of drugs and their effects on the human body encompasses all aspects of sex, including desire, performance, pleasure, conception, gestation, and disease.

<span class="mw-page-title-main">Psychoactive drug</span> Chemical substance that alters nervous system function

A psychoactive drug, psychopharmaceutical, psychoactive agent, or psychotropic drug is a chemical substance that changes the function of the nervous system and results in alterations of perception, mood, cognition, and behavior. These substances may be used medically, recreationally, for spiritual reasons, or for research. Some categories of psychoactive drugs may be prescribed by physicians and other healthcare practitioners because of their therapeutic value.

<span class="mw-page-title-main">Hamilton Morris</span> American journalist (born 1987)

Hamilton Morris is an American journalist, documentarian, and scientific researcher. He is the creator and director of the television series Hamilton's Pharmacopeia, in which he investigates the chemistry, history, and cultural impact of various psychoactive drugs.

<span class="mw-page-title-main">Methoxphenidine</span> Chemical compound

Methoxphenidine is a dissociative of the diarylethylamine class that has been sold online as a designer drug. Methoxphenidine was first reported in a 1989 patent where it was tested as a treatment for neurotoxic injury. Shortly after the 2013 UK ban on arylcyclohexylamines methoxphenidine and the related compound diphenidine became available on the gray market, where it has been encountered as a powder and in tablet form. Though diphenidine possesses higher affinity for the NMDA receptor, anecdotal reports suggest methoxphenidine has greater oral potency. Of the three isomeric anisyl-substituents methoxphenidine has affinity for the NMDA receptor that is higher than 4-MeO-Diphenidine but lower than 3-MeO-Diphenidine, a structure–activity relationship shared by the arylcyclohexylamines.

Psychedelic microdosing involves consuming sub-threshold doses (microdoses) of serotonergic psychedelic drugs like LSD and psilocybin to potentially enhance creativity, energy, emotional balance, problem-solving abilities, and to address anxiety, depression, and addiction. This practice has gained popularity in the 21st century.

Drug checking or pill testing is a way to reduce the harm from drug consumption by allowing users to find out the content and purity of substances that they intend to consume. This enables users to make safer choices: to avoid more dangerous substances, to use smaller quantities, and to avoid dangerous combinations.

Psychedelic treatments for trauma-related disorders are the use of psychedelic substances, either alone or used in conjunction with psychotherapy, to treat trauma-related disorders. Trauma-related disorders, such as post-traumatic stress disorder (PTSD), have a lifetime prevalence of around 8% in the US population. However, even though trauma-related disorders can hinder the everyday life of individuals with them, less than 50% of patients who meet criteria for PTSD diagnosis receive proper treatment. Psychotherapy is an effective treatment for trauma-related disorders. A meta-analysis of treatment outcomes has shown that 67% of patients who completed treatment for PTSD no longer met diagnostic criteria for PTSD. For those seeking evidence-based psychotherapy treatment, it is estimated that 22-24% will drop out of their treatment. In addition to psychotherapy, pharmacotherapy (medication) is an option for treating PTSD; however, research has found that pharmacotherapy is only effective for about 59% of patients. Although both forms of treatment are effective for many patients, high dropout rates of psychotherapy and treatment-resistant forms of PTSD have led to increased research in other possible forms of treatment. One such form is the use of psychedelics.

<span class="mw-page-title-main">Drugs and sexual consent</span>

Drugs and sexual consent is a topic that discusses the impacts of drugs on sexual activity that lead to changes in sexual consent. Sexual consent is the voluntary agreement to engage in sexual activity, which is essential in preventing sexual violence. Consent can be communicated verbally or nonverbally and should be freely offered. However, drug use, particularly psychoactive drugs that alter mental processes, can affect people’s decision-making and consent communication ability, potentially impacting the autonomous aspect of sexual consent.

References

  1. 1 2 3 4 Anderson, Laurie S.; Bell, Heidi G; Gilbert, Michael; Davidson, Julie E; Winter, Christina; Barratt, Monica J; Win, Beta; Painter, Jeffery L; Menone, Christopher; Sayegh, Jonathan; Dasgupta, Nabarun (2017-02-01). "Using Social Listening Data to Monitor Misuse and Nonmedical Use of Bupropion: A Content Analysis". JMIR Public Health and Surveillance. 3 (1): e6. doi: 10.2196/publichealth.6174 . ISSN   2369-2960. PMC   5311422 . PMID   28148472.
  2. 1 2 3 4 5 Chiauzzi, Emil; Dasmahapatra, Pronabesh; Lobo, Kimberly; Barratt, Monica J. (June 2013). "Participatory research with an online drug forum: a survey of user characteristics, information sharing, and harm reduction views". Substance Use & Misuse. 48 (8): 661–670. doi:10.3109/10826084.2013.800117. ISSN   1532-2491. PMID   23750771. S2CID   207520485.
  3. ↑ Aubusson, Kate (2016-11-16). "Drug users swap stories, share warnings online in search for safety". The Sydney Morning Herald. Retrieved 2020-11-14.
  4. ↑ Johnson, Doug (2019-10-18). "To Tackle Drug Use, Researchers and People With Addiction Alike Turn to Online Forums". Undark Magazine. Archived from the original on 2021-09-16. Retrieved 2020-11-14.
  5. ↑ "Site Info". Alexa. 2016. Archived from the original on January 16, 2017. Retrieved January 16, 2017.
  6. ↑ "Forum list". Bluelight.org. 2024-02-04. Retrieved 2024-02-04.
  7. ↑ Ward, Jeanine; Rhyee, Sean; Plansky, Jason; Boyer, Edward (November 2011). "Methoxetamine: a novel ketamine analog and growing health-care concern". Clinical Toxicology. 49 (9): 874–875. doi:10.3109/15563650.2011.617310. ISSN   1556-9519. PMID   21981756. S2CID   28388437.
  8. 1 2 Barratt, Monica J.; Allen, Matthew; Lenton, Simon (June 2014). ""PMA sounds fun": negotiating drug discourses online". Substance Use & Misuse. 49 (8): 987–998. doi:10.3109/10826084.2013.852584. hdl: 20.500.11937/35817 . ISSN   1532-2491. PMID   24779498. S2CID   41509447.
  9. ↑ Deluca, Paolo; Davey, Zoe; Corazza, Ornella; Di Furia, Lucia; Farre, Magi; Flesland, Liv Holmefjord; Mannonen, Miia; Majava, Aino; Peltoniemi, Teuvo; Pasinetti, Manuela; Pezzolesi, Cinzia; Scherbaum, Norbert; Siemann, Holger; Skutle, Arvid; Torrens, Marta; Van Der Kreeft, Peer; Iversen, Erik; Schifano, Fabrizio (2012-12-03). "Identifying emerging trends in recreational drug use; outcomes from the Psychonaut Web Mapping Project". Progress in Neuro-Psychopharmacology and Biological Psychiatry. 39 (2): 221–226. doi:10.1016/j.pnpbp.2012.07.011. ISSN   0278-5846. PMID   22841965. S2CID   22296279.
  10. ↑ Carhart-Harris, R. L.; King, L. A.; Nutt, D. J. (2011-10-01). "A web-based survey on mephedrone". Drug and Alcohol Dependence. 118 (1): 19–22. doi:10.1016/j.drugalcdep.2011.02.011. ISSN   1879-0046. PMID   21420252.
  11. ↑ Kettner, H.; Rosas, F. E.; Timmermann, C.; Kärtner, L.; Carhart-Harris, R. L.; Roseman, L. (2021). "Psychedelic Communitas: Intersubjective Experience During Psychedelic Group Sessions Predicts Enduring Changes in Psychological Wellbeing and Social Connectedness". Frontiers in Pharmacology. 12. doi: 10.3389/fphar.2021.623985 . ISSN   1663-9812. PMC   8114773 . PMID   33995022.
  12. ↑ Davis, Alan K; Clifton, John M; Weaver, Eric G; Hurwitz, Ethan S; Johnson, Matthew W; Griffiths, Roland R (September 2020). "Survey of entity encounter experiences occasioned by inhaled N,N -dimethyltryptamine: Phenomenology, interpretation, and enduring effects". Journal of Psychopharmacology. 34 (9): 1008–1020. doi: 10.1177/0269881120916143 . ISSN   0269-8811. PMID   32345112.
  13. ↑ "Completed - Quick survey on the interactions between psilocybin mushrooms and antidepressants". Bluelight.org. 2020-09-25. Retrieved 2024-02-05.
  14. ↑ "Recruiting - Johns Hopkins survey on HPPD: Help us uncover new insights into the condition and its treatment". Bluelight.org. 2023-05-23. Retrieved 2024-02-05.
  15. ↑ Young, Matthew M.; Dubeau, Chad; Corazza, Ornella (2015-02-16). "Detecting a signal in the noise: monitoring the global spread of novel psychoactive substances using media and other open-source information". Human Psychopharmacology: Clinical and Experimental (published 2015-07-28). 30 (4): 319–326. doi:10.1002/hup.2477. ISSN   0885-6222. PMC   4584493 . PMID   26216568.
  16. ↑ Soussan, Christophe; Kjellgren, Anette (2016-06-01). "The users of Novel Psychoactive Substances: Online survey about their characteristics, attitudes and motivations". International Journal of Drug Policy. 32: 77–84. doi:10.1016/j.drugpo.2016.03.007. ISSN   0955-3959. PMID   27184218.
  17. ↑ Barratt, Monica J.; Cakic, Vince; Lenton, Simon (March 2013). "Patterns of synthetic cannabinoid use in Australia". Drug and Alcohol Review. 32 (2): 141–146. doi:10.1111/j.1465-3362.2012.00519.x. ISSN   0959-5236. PMID   23043552.
  18. ↑ Polito, Vince; Stevenson, Richard J. (2019-02-06). "A systematic study of microdosing psychedelics". PLOS ONE. 14 (2): e0211023. Bibcode:2019PLoSO..1411023P. doi: 10.1371/journal.pone.0211023 . ISSN   1932-6203. PMC   6364961 . PMID   30726251.
  19. ↑ "Recruiting - Anonymous Survey Study on Psychedelic Use in Romantic Relationships - Columbia University". Bluelight.org. 2022-05-16. Retrieved 2024-02-05.
  20. ↑ "Recruiting - RESEARCH VOLUNTEERS: Healthy heroin users". Bluelight.org. 2022-12-23. Retrieved 2024-02-05.
  21. ↑ "Recruiting - [USA] Community Health Discussion Session/Survey Study (Reimbursement up to $225)". Bluelight.org. 2023-09-21. Retrieved 2024-02-05.
  22. 1 2 Kruger, Daniel J.; Enghoff, Oskar; Herberholz, Moss; Barron, Julie; Boehnke, Kevin F. (2023-10-20). ""How Do I Learn More About this?": Utilization and Trust of Psychedelic Information Sources Among People Naturalistically Using Psychedelics". Journal of Psychoactive Drugs. 55 (5): 631–639. doi:10.1080/02791072.2023.2201263. ISSN   0279-1072. PMID   37078418. S2CID   258237524.
  23. ↑ Glynos, Nicolas G.; Fields, Christopher W.; Barron, Julie; Herberholz, Moss; Kruger, Daniel J.; Boehnke, Kevin F. (2023-08-08). "Naturalistic Psychedelic Use: A World Apart from Clinical Care". Journal of Psychoactive Drugs. 55 (4): 379–388. doi:10.1080/02791072.2022.2108356. ISSN   0279-1072. PMID   35950817. S2CID   251494820.
  24. ↑ Kruger, Daniel J.; Glynos, Nicolas G.; Fields, Christopher W.; Herberholz, Moss; Boehnke, Kevin F. (2023-08-08). "An Assessment of Psychedelic Knowledge Among People Using Psychedelics Naturalistically". Journal of Psychoactive Drugs. 55 (4): 420–424. doi:10.1080/02791072.2022.2142709. ISSN   0279-1072. PMID   36328419. S2CID   253303071.
  25. ↑ Kruger, Daniel J.; Barron, Julie; Herberholz, Moss; Boehnke, Kevin F. (2023-10-20). "Preferences and Support for Psychedelic Policies and Practices Among Those Using Psychedelics". Journal of Psychoactive Drugs. 55 (5): 650–659. doi:10.1080/02791072.2023.2228784. ISSN   0279-1072. PMID   37353935. S2CID   259240648.
  26. ↑ Boehnke, Kevin F.; Cox, Kasey; Weston, Cody; Herberholz, Moss; Glynos, Nicolas; Kolbman, Nicholas; Fields, Christopher W.; Barron, Julie; Kruger, Daniel J. (2023). "Slouching towards engagement: interactions between people using psychedelics naturalistically and their healthcare providers". Frontiers in Psychiatry. 14. doi: 10.3389/fpsyt.2023.1224551 . ISSN   1664-0640. PMC   10436225 . PMID   37599880.
  27. ↑ "Recruiting - Amplifying Community Voices Through Science — We want to hear about YOUR experiences with psychedelics". Bluelight.org. 2023-10-27. Retrieved 2024-02-05.
  28. ↑ "Writing-up - Psychedelic Drug Experiences Survey". Bluelight.org. 2020-03-04. Retrieved 2024-02-05.
  29. 1 2 "Bluelight - MAPS.org partnership!". Bluelight.org. 2007-02-14. Retrieved 2024-02-04.
  30. 1 2 Pereira, Margaret; Scott, John (2017-01-02). "Harm reduction and the ethics of drug use: contemporary techniques of self-governance". Health Sociology Review. 26 (1): 69–83. doi:10.1080/14461242.2016.1184583. ISSN   1446-1242. S2CID   148474622.
  31. 1 2 "Bluelight.org". Discord Servers. Retrieved 2024-02-04.
  32. 1 2 "Bluelight Social Media Links + Discord". Bluelight.org. 2022-02-10. Retrieved 2024-02-04.
  33. 1 2 3 4 "Bluelight.org - Discord Servers". Discord. Retrieved 2024-02-04.
  34. 1 2 3 4 5 Nichols, Sam (2019-05-06). "How 'Bluelight' Became a Life-Saving Encyclopedia of Drug Info". Vice. Retrieved 2024-03-01.
  35. 1 2 "Bluelight History". Bluelight.org. Retrieved 2024-02-04.
  36. ↑ "Bluelight - Powered by vBulletin". 2006-01-01. Archived from the original on 2006-01-01. Retrieved 2024-03-01.
  37. ↑ "New website and branding for Bluelight has landed!". Bluelight.org. 2024-03-08. Retrieved 2024-03-18.
  38. ↑ "Bluelight Announcement". MAPS. 5 April 2013. Archived from the original on 2021-10-21. Retrieved 2020-11-14.
  39. ↑ Simonini, Ross (2012-02-10). "A Psychonaut's Adventures in Videoland". The New York Times. ISSN   0362-4331 . Retrieved 2024-02-29.
  40. ↑ Davis, Joshua. "John McAfee Fled to Belize, But He Couldn't Escape Himself". Wired. ISSN   1059-1028. Archived from the original on 2024-02-23. Retrieved 2024-02-29.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.